The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The facility is expected to become operational by FY2028-29
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Subscribe To Our Newsletter & Stay Updated
